Receive our newsletter – data, insights and analysis delivered to you
June 3, 2009

Arbor Unveils New ‘Swimmer’s Ear’ Treatment

Arbor Pharmaceuticals has unveiled ZINOTIC ES, a new treatment for children suffering with Acute Otitis Externa (AOE), also known as 'swimmer's ear'. ZINOTIC ES is an extra-strength formulation of original ZINOTIC. It provides extra pain relief and skin protection for children suffering f

By cms admin

Arbor Pharmaceuticals has unveiled ZINOTIC ES, a new treatment for children suffering with Acute Otitis Externa (AOE), also known as ‘swimmer’s ear’.

ZINOTIC ES is an extra-strength formulation of original ZINOTIC. It provides extra pain relief and skin protection for children suffering from AOE.

AOE or swimmer’s ear is a common childhood infection of the ear canal characterised by intense pain and inflamed, damaged skin.

Arbor Pharmaceuticals president and CEO Jarrett Disbrow said that ZINOTIC had become an important AOE treatment option since its introduction.

“The new ZINOTIC ES will be a welcome addition to the ZINOTIC franchise as it further addresses the three AOE treatment goals with its enhanced, extra-strength formulation,” he said.

AOE treatment should address three main goals including treating the infection, relieving the pain and restoring the integrity of the lining of the ear canal.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU